Latest Ebos Group News

Algorae Pharmaceuticals has broadened its commercial footprint in Australia and New Zealand through key licensing agreements, while advancing its AI-driven drug discovery platform and strengthening leadership.

EBOS Group Limited has updated its final dividend details for the six months ending June 2025, confirming a fully franked ordinary dividend and specifying the Dividend Reinvestment Plan strike price.

S&P Dow Jones Indices has announced its September 2025 quarterly rebalance, with significant additions and removals across multiple ASX indices set to take effect before market open on September 22.

EBOS Group Limited reported a 7% drop in revenue and a 21% fall in net profit for FY2025, reflecting ongoing cost pressures and restructuring impacts. The company declared a final dividend, signaling cautious optimism despite the earnings setback.

EBOS Group Limited reported solid FY25 results with 12% revenue growth and strategic acquisitions, setting sights on continued expansion and operational efficiency in FY26.

EBOS Group Limited reported a steady FY25 with 12% revenue growth and EBITDA in line with guidance, driven by strong healthcare and animal care segments. The company signals confidence with maintained dividends and a positive FY26 outlook.

EBOS Group Limited has reported a 7% decline in revenue and a 21% drop in net profit for FY2025, yet it maintains its final dividend at 61.5 NZ cents per share. The results reflect ongoing cost pressures and restructuring expenses amid a challenging market environment.

Biome Australia Limited has reported a 69% increase in international sales revenue for FY25, reaching $1.5 million, driven by new strategic distribution agreements across Ireland, New Zealand, and Canada.

LTR Pharma has expanded patient access to its fast-acting erectile dysfunction treatment SPONTAN by partnering with TerryWhite Chemmart’s extensive pharmacy network, marking a significant step in its commercial rollout and regulatory strategy.

EBOS Group Limited has announced a fully franked interim dividend of NZD 0.595 per share for the half-year ending December 2024, alongside a Dividend Reinvestment Plan offering a 2.5% discount.

EBOS Group Limited announces the retirement of CEO John Cullity after a decade of strong growth, appointing Adam Hall as his successor to lead the company’s next phase of expansion.

EBOS Group Limited’s interim results for H1 2025 reveal a notable decrease in revenue and profit compared to the prior year, yet the company maintains its interim dividend, signaling confidence despite headwinds.